{
  "protocol_content": "# A Randomized Trial of Novel Drug X in Patients with Hypertension\n\n**Protocol Number:** RCT-DEMO-2024-001\n**Principal Investigator:** Dr. Sarah Wilson, MD, PhD\n**Study Phase:** Phase III\n**Version:** 1.0\n**Date:** February 04, 2026\n\n## Protocol Synopsis\n\n**Background:** This randomized controlled trial is designed to evaluate the efficacy and safety of the investigational treatment.\n\n**Primary Objective:** To evaluate the efficacy of Drug X in reducing systolic blood pressure compared to placebo\n\n**Secondary Objectives:** To assess safety, tolerability, and quality of life improvements\n\n**Study Design:** Randomized, double-blind, placebo-controlled, parallel-group study\n\n**Study Population:** Adults aged 18-75 with essential hypertension\n\n**Sample Size:** 400 participants\n\n## Study Objectives\n\n### Primary Objective\nTo evaluate the efficacy of Drug X in reducing systolic blood pressure compared to placebo\n\n### Secondary Objectives\nTo assess safety, tolerability, and quality of life improvements\n\n## Study Design\n\n**Design Type:** Parallel Group\n**Randomization:** Central randomization with stratification\n**Blinding:** Double-blind (participant and investigator)\n**Treatment Duration:** 12 weeks\n\n### Treatment Groups\n- **Group A:** Investigational Drug\n- **Group B:** Placebo\n\n## Statistical Considerations\n\n**Primary Endpoint:** Change from baseline in primary efficacy measure\n\n**Sample Size Calculation:**\n- Target Sample Size: 400 participants\n- Power: 90%\n- Alpha Level: 0.05\n- Expected Effect Size: 0.5\n\n**Statistical Analysis:** Mixed model repeated measures (MMRM) analysis\n\n## Study Procedures\n\n### Screening Period\nParticipants will undergo comprehensive screening to determine eligibility.\n\n### Treatment Period  \nEligible participants will be randomized to receive either investigational treatment or placebo.\n\n### Follow-up Period\nSafety follow-up will continue for 30 days after last dose.\n\n---\n\n*This protocol was generated using the Enhanced Protocol Generation System with PHI compliance and regulatory framework support.*\n\n**Generated:** 2026-02-04 04:26:54\n**Template:** RCT Basic v1.0\n**Compliance:** HIPAA, ICH-GCP\n",
  "template_id": "rct_basic"
}